Molecular biology in the diagnosis of lung cancer;Molekylærbiologisk diagnostikk ved lungekreft

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 23, 2005, Pages 3283-3285

  Haugen, Aage ^a  

^a NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; GENE EXPRESSION PROFILING; HUMAN; LUNG CARCINOGENESIS; LUNG CARCINOMA; MOLECULAR RECOGNITION; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN METHYLATION; PROTO ONCOGENE; REVIEW; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; ARTICLE; DIAGNOSTIC PROCEDURE; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; PATHOLOGY; PROTEOMICS; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

TUMOR MARKER;

ADENOCARCINOMA; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33644799325     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Zöchbauer-Müller S, Gazdar A, Minna J. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002; 64: 681-708.
2. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
3. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004; 64: 8919-23.
4. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 1-11.
5. Wistuba I, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002; 21: 7298-306.
6. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-8.
7. Honorio S, Agathanggelou A, Schuermann M et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and breast cancer patients. Oncogene 2003; 22: 147-50.
8. Yokota I, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004; 95: 197-204.
9. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-5.
10. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784-9.
11. Sugita M, Geraci M, Gao B et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002; 62: 3971-9.
12. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-24.
13. Petty RD, Nicolson MC, Kerr KM et al. Gene expression profiling in non-small cell lung cancer: From molecular mechanisms to clinical application. Clin Cancer Res 2004; 10: 3237-48.
14. Tomida S, Koshikawa K, Yatabe Y et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004; 23: 5360-70.
15. Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol 2004; 31: 4-19.